High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals

Authors:

Abstract
No abstract available
All Related Versions
Funding Information
  • National Institutes of Health (AI120898, AI122390, DA046100, R01AI158617, U19AI082630, UM1AI148574)
  • Eli Lilly and Company
  • Pfizer
  • Merck